Longeveron Inc.

Hello everyone and welcome to the Longevity Run in 2022 first quarter earnings call. My name is Juan and I will be coordinating your call today. All participants have been placed on mute to prevent any background noise. There will be a question and answer session at the end of the presentation. If you would like to ask a question at that time, please press star followed by number one on your telephone keypad. I would now like to turn the call over to Elsie Zhao from Stern Investor Relations. Please, Elsie, you may proceed.

Thank you, Operator. Good morning, everyone, and welcome to Longevira's first quarter 2022 call. Today, we'll provide a business update and discuss financial results for the first quarter of 2022. Earlier this morning, we issued a press release with these results, which can be found under the Investors section of our website at www.longevira.com. I'm joined in the call today by the following members of Longeviron's management team, Jeff Green, Chief Executive Officer, Dr. Joshua M. Hare, Co-Founder, Chief Science Officer and Chairman, Dr. Chris Min, Chief Medical Officer, and James Covijo, Chief Financial Officer. Mr. Green will begin with a brief corporate overview, followed by Dr. Min, who will provide updates to our clinical pipeline, And finally, Mr. Colvijo will review our 2022 first quarter financial results. We will then open the call for Q&A. As a reminder during this call, we will be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factor discussions in our filings of the FTC including our annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now, I'd like to turn the call over to Jeff Green, Chief Executive Officer of Longeviron. Jeff?

Thank you, Elsie. Good morning, everyone. It's my pleasure to welcome you to Longeviron's first quarter 2022 business update and financial results call. Longevron is a leading clinical stage biotechnology company developing living cell therapies for chronic aging-related diseases and other specific life-threatening conditions. We are driven by our mission to develop safe and effective cell-based therapies for some of the most challenging disorders associated with the aging process and other medical disorders. In the first quarter of 2022, we continue to make progress advancing our lead investigational cell therapy product, LomaCellB, through clinical development for multiple indications. with ongoing trials in Alzheimer's disease, hypoplastic left heart syndrome, or HLHS, and acute respiratory distress syndrome, or ARDS. As a reminder, our lead investigational product called LomaCellB is a living cell product made from the specialized cells isolated from the bone marrow of young, healthy adult donors aged 18 to 45. These specialized multipotent cells, known in the literature as medicinal signaling cells, or MSCs, reside in different concentrations within various tissues in our bodies and are our endogenous or built-in repair mechanism. MSCs are known to perform a number of complex functions, including the ability to form new tissue and home to sites of injury or disease, and to create bioactive factors that are immunomodulatory and regenerative. We believe that Loma cell B may have multimodal mechanisms of action that leads to anti-inflammatory, provascular, or improved vascular and endothelial function, and regenerative and repair responses. Through clinical testing, we hope to show that Lomacil-B could be a potential clinical therapy for a range of aging-related and rare diseases. Now, before turning the call over to Dr. Min, I'd like to take a moment to address the announcement we made on Monday, May 9th regarding the CEO transition to occur on June 1st. After more than six years with Longeviron at a variety of leadership positions that included senior vice president, president and chief executive officer, I made the decision to step down as CEO in order to pursue new opportunities. My time with Longevron has been a very rewarding experience, participating in fantastic growth and progress, an initial public offering, raising nearly $50 million in 2021, and expanding Longevron's executive management team. At the request of our board of directors, Dr. Chris Min, current chief medical officer, has agreed to serve as interim CEO while the company engages in a nationwide search for a permanent CEO. I have full confidence in Dr. Min and know this will be a smooth transition. I'll miss all my fantastic colleagues at Longevron. It has been an eventful and rewarding journey for me, but it is time to let someone else take the helm. The company has dedicated and hardworking employees, a seasoned executive leadership team, a strong board, an exciting lead therapeutic in LomasLB, promising preliminary clinical data, and a healthy balance sheet, and I look forward to following the company's path and progress closely. Now, for specific updates regarding our clinical programs, I turn it over to Dr. Chris Min, Chief Medical Officer and future interim CEO. Chris? Thank you, Jeff.